Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642941 · ClinicalTrials.gov registry record · Phase 2
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT00642941 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 317 participants.
The verdict
NCT00642941, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.
Interventions
- DRUG RG1507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2007-12-18 |
| Est. Completion | 2014-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642941
The ClinicalTrials.gov registry entry for NCT00642941 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RG1507 is the first listed.
NCT00642941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642941 about?
NCT00642941 is a clinical study titled "A Study of R1507 in Participants With Recurrent or Refractory Sarcoma". The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part s...
What is the current status of trial NCT00642941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2007-12-18. Estimated completion is 2014-02-19.
What interventions are being tested in trial NCT00642941?
The interventions under investigation include: RG1507 (DRUG).
Who is sponsoring clinical trial NCT00642941?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.